Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Xylamidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylamidine SCHEMBL31307218 | 0.89 | MTNR1A (0.58) | MTNR1AMTNR1BALDH1A1POLBMAOB | |
| Xylamidine SCHEMBL12481373 | 0.84 | LMNA (0.40) | MTNR1AMTNR1BPKML3MBTL1ALDH1A1 | |
| Xylamidine SCHEMBL30201100 | 0.84 | MTNR1A (0.53) | MTNR1AMTNR1BALDH1A1MAOB | |
| SCHEMBL30201287 | 0.73 | MTNR1A (0.56) | MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL31231248 | 0.69 | MTNR1A (0.48) | MTNR1AMTNR1BL3MBTL1ALDH1A1 | |
| SCHEMBL7539405 | 0.68 | PKM (0.50) | PKML3MBTL1POLB | |
| SCHEMBL31231364 | 0.68 | MTNR1A (0.56) | MTNR1AMTNR1BALDH1A1RECQL | |
| SCHEMBL30200767 | 0.67 | MTNR1A (0.42) | MTNR1AMTNR1BALDH1A1 | |
| Xylamidine SCHEMBL2107805 | 0.66 | MAOB (0.47) | MTNR1AMTNR1BMAOB | |
| SCHEMBL30200879 | 0.66 | MTNR1A (0.55) | MTNR1AMTNR1BL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | MCMASTER UNIVERSITY (CA) | 2022-03-22 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20090220429-A1 | METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | METIS CURA EHF (IS) | 2009-09-03 | — | — | US | claimed |
| CN-101155548-A | Methods and systems for assessing neurological conditions | MENTIS CURA EHF (IS) | 2008-04-02 | — | — | CN | claimed |
| EP-1861003-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | Mentis Cura ehf. (IS) | 2007-12-05 | — | — | EP | claimed |
| WO-2006094797-A1 | A METHOD AND A SYSTEM FOR ASSESSING NEUROLOGICAL CONDITIONS | MENTIS CURA EHF. (IS) | 2006-09-14 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11278549-B2 | Method of treating obesity | GPR119, HTR2A, GIPR | MTNR1A 14/4885MTNR1B 11/4885PKM 2391/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | MTNR1A 490/4885MTNR1B 641/4885PKM 2367/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | MTNR1A 3999/4885MTNR1B 4039/4885PKM 194/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | MTNR1A 458/4885MTNR1B 382/4885PKM 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.